Paper Details

  1. Home
  2. Paper Details

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.

Author: , EronJoseph J, EsserStefan, HufkensVeerle, JezorwskiJohn, LathouwersErkki, OpsomerMagda, OrkinChloe, PodzamczerDaniel, RockstrohJürgen, Van LanduytErika, VandekerckhoveLinos

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) resulted in high virologic response and low virologic failure rates in treatment-naive HIV-1-positive adults over 96 weeks. No resistance development to darunavir or TAF/TDF was observed. Bone, renal, and lipid safety were consistent with known D/C/F/TAF component profiles.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated through 96 weeks in AMBER (NCT02431247). METHODS: Treatment-naive, HIV-1-positive adults [screening plasma viral load ≥1000 copies/ml; CD4 cell count >50 cells/μl) were randomized (1 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/31833849

データ提供：米国国立医学図書館（NLM）

Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: A Promising Treatment for HIV-1

This study delves into the promising realm of [HIV-1 treatment], exploring the effectiveness of [Darunavir/cobicistat/emtricitabine/tenofovir alafenamide] in [Treatment-naive patients]. The research uses [A phase 3 trial] to investigate [The long-term efficacy and safety of the drug regimen]. The authors uncover [High virologic response and low virologic failure rates] and suggest that [Darunavir/cobicistat/emtricitabine/tenofovir alafenamide] is a [Safe and effective treatment option for HIV-1]. This study, like a beacon in the desert of [HIV research], offers hope for [Patients seeking effective treatment].

A Powerful Weapon Against HIV-1

This study reveals that [Darunavir/cobicistat/emtricitabine/tenofovir alafenamide] is a [Highly effective treatment] for [HIV-1 infection]. It's like finding a powerful weapon to fight a formidable enemy. The study found that [The drug regimen resulted in sustained viral suppression] in [A majority of patients] over [A 96-week period].

Hope for the Future: A Safe and Effective Treatment

This study highlights the importance of [Safe and effective treatment options] for [HIV-1]. This research suggests that [Darunavir/cobicistat/emtricitabine/tenofovir alafenamide] is a promising [Long-term treatment] option for [Patients with HIV-1]. It's like finding a stable oasis in the desert, providing [A safe haven] for those seeking relief.

Dr.Camel's Conclusion

This study provides compelling evidence that [Darunavir/cobicistat/emtricitabine/tenofovir alafenamide] is a [Safe and effective treatment] for [HIV-1 infection] in [Treatment-naive patients]. It offers hope for [Improved outcomes] for those seeking [Effective long-term management of HIV-1].

Date :
  1. Date Completed 2021-02-18
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

31833849

DOI: Digital Object Identifier

00002030-202004010-00007

Related Literature

Article Analysis
・Effects of darunavir and cobicistat
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.